WREXHAM, UK, 13 June 2023 – Ipsen today announced a £75 million investment in its Wrexham site, a world-renowned “neuroscience centre of excellence.” The announcement coincides with the site’s 50th birthday, which was celebrated with a tree-planting ceremony attended by the newly appointed Wrexham Mayor, members of the community, and Ipsen employees, including the company’s Chief Executive Officer, David Loew.
The event commemorated half a century of researching, developing and manufacturing innovative treatments for patients in over 90 countries across the world, with the tree-planting ceremony serving as a symbol of the company’s strong roots in North Wales, sustainable work practices, commitment to the environment, and future growth.
Wrexham’s new Mayor, Councillor Andy Williams, who took part in the tree-planting ceremony, said, “Today marks a significant milestone for Ipsen as a company, and for the Wrexham community. Through the creation of numerous jobs over five decades, Ipsen’s Wrexham site has contributed significantly to the growth of the local economy while working sustainably and ethically, making it a shining example to businesses locally and globally. From driving global health to ‘going green’ and helping local students pursue careers in the life sciences sector, Ipsen Wrexham has much to be proud of as a community partner and global innovator.”
Ipsen Wrexham, which is the largest of Ipsen’s UK sites, uses 100% renewable energy across its production and research units. Earlier in the year, the Wrexham-based global manufacturing site was awarded a grant by the government in recognition of its outstanding contributions to the life sciences ecosystem.
“The 50th anniversary of Ipsen’s Wrexham site marks a proud moment for our company,” said David Loew. “We have seen huge growth in demand at this important site, and we are pleased to continue our investment in the area and contribute positively to the local economy.”
Ipsen Wrexham is a global site, producing products that are exported to more than 90 countries around the world. It currently houses approximately 500 Ipsen employees, including scientists focused on developing a range of scientifically advanced, high-quality processes and methodologies required for the manufacture and supply of clinical products across the Ipsen Biologics portfolio. It was recently named as one of the UK’s Best Workplaces™ (2023) in the category of large organisations, by Great Place to Work®, the global authority on workplace culture.
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,400 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com
For further information:
Senior Communications and Patient Affairs Manager,
UK & Ireland Global Hub
+44 (0)7514 492568
Communications and Patient Affairs Manager, UK & Ireland Global Hub
+44 (0)7731 981010
Ipsen’s forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.